A technique was developed to evaluate the potency of ligand binding at M, ACh receptors and to experimentally localize the M, and M, subtypes to specific neuronal processes.
Normal and experimental material was prepared with tritiated ligand binding to cryostat-sectioned area 29c of posterior cingulate cortex in rat, coverslip autoradiography, and single-grain-counting techniques. Three fundamental issues were addressed.
1. A morphological criterion termed an index of heterogeneity was developed by which the specificity of M, binding by different ligands could be assessed.
The index was calculated by first determining the laminar distribution of pirenzepine (PZ) binding sites and then summing absolute laminar variations from this distribution for each ligand. According to this measure the most efficient protocol for assaying M, sites was tritiated oxotremorine-M (0X0) coincubated in unlabeled PZ (5 x 1O-8 M Finally, in contrast to PZ-blocked OX0 and PrBCM binding, binding of PZ-blocked 3H-quinuclidinyl benrilate (QNB) was reduced to homogeneity following ATN lesions.
3. Cortical pyramidal neurons have dendritic receptors that are primarily of the M, subtype but may also include M, sites. Thus, full depth ibotenic acid lesions reduced PZ binding by almost 70%. Neurotoxin lesions of neurons in layers II-IV or Vb-VI were followed by degeneration of the apical dendrites of pyramids in layer I and 78 and 15% reductions, respecReceived Apr. 13, 1987; revised Aug. 13, 1987; accepted Aug. 21, 1987 . We thank Drs. Ladislav Volicer, Enzio Muller, and Ellen Townes-Anderson for reading and commenting on the manuscript. This research was supported by NIH Grant NS 18745. Correspondence should be addressed to Brent A. Vogt Two muscarinic ACh receptors have been characterized primarily on the basis of agonist binding properties (Birdsall et al., 1978; Wamsley et al., 1980; Hammer and Giachetti, 1982; Potter et al., 1984) . The nonclassical antagonist pirenzepine (PZ) binds with a higher affinity to the M, than the M, site (Hammer et al., 1980; Watson et al., 1983; Wamsley et al., 1984) , and regional analyses of PZ binding suggest that it binds to a subpopulation of sites recognized by classical antagonists such as quinuclidinyl benzilate (QNB) (Watson et al., 1983; Yamamura et al., 1983; Wamsley et al., 1984; Watson et al., 1986) . In contrast, the muscarinic receptor agonist oxotremorine-M (0X0) binds with a higher affinity to M, than M, sites and can be used to identify M, sites in homogenized or cryomicrotome-sectioned tissue Birdsall and Hulme, 1983; Spencer et al., 1986) . Another approach to identifying M, sites is to block the M, component of classical antagonist binding with PZ (Luthin and Wolfe, 1984; Potter et al., 1984; Palacios et al., 1986) . As yet there are no criteria by which to directly assess strategies for localizing M, sites in cryomicrotome sections. Although there is no direct morphological evidence for the cellular localization of M, or M, sites, electrophysiological and biochemical studies are suggestive. Thus, M,, or PZ-sensitive, sites may be postsynaptic on pyramidal neurons, since PZ blocks ACh-evoked depolarizations Prince, 1985, 1986) . Furthermore, there is biochemical support for presynaptic localization of M, sites on cholinergic (Ganguly and Das, 1979; Nordstrom and Bartfai, 1980; Zarbin et al., 1982; Raiteri et al., 1984; Mash et al., 1985) and dopaminergic (De Belleroche et al., 1982; Raiteri et al., 1984) axons.
The laminar and nuclear distributions of M, and M, sites have been analyzed Potter et al., 1984;  of Cortical Muscarinic Receptor Subtypes Wamsley et al., 1984; Palacios et al., 1986; Spencer et al., 1986; Watson et al., 1986) ; however, these studies cannot determine the location of muscarinic receptors on specific neurons and/or afferent axons. Although cells can be dissociated and specific binding determined autoradiographically for identified types of adult neurons (Vogt et al., 1987) there are limitations to this approach. First, the only ligands appropriate for wet emulsion autoradiography are those that are irreversible, but propylbenzilylcholine mustard (PrBCM), which is irreversible, is not selective for a receptor subtype. Since PZ is reversible, this ligand ofchoice for the M, receptor is not suitable for assaying receptors on dissociated neurons. Second, extensive pruning of the dendritic and axonal trees occurs during dissociation. Thus, spines, entire apical tufts, and the axonal arbors are removed. Third, this approach cannot be used to address localization to afferent axons since the identity of axonal processes are lost following dissociation. An experimental approach to receptor subtype localization that overcomes the shortcomings of the dissociation technique is the placement of restricted lesions and evaluation of subsequent alterations in binding. Pivotal to developing these studies are heterogeneities in the distribution of dendrites and afferent terminations as well as receptor subtype distribution. Matches in these heterogeneities serve as the basis for lesion placement. Ablation specificity determines, in part, the resolution of this technique. In the present study, for example, neurotoxin lesions of only a few layers allow for assessing receptor subtypes on apical dendritic tufts.
The present study used laminar heterogeneities in the distribution of afferent axons, dendrites, and receptor subtypes to develop methods for comparing the binding of various ligands to the M, receptor. Optimal protocols were used following single or multiple ablations to localize muscarinic receptor subtypes in cingulate cortex. Of particular note is the use of laminar neurotoxin lesions for the study of PZ binding to pyramidal cell apical dendritic tufts.
Materials and Methods
Thalamic and cortical ablations were made as previously reported (Vogt, 1984) in 96 hooded, Long-Evans male rats (300-350 gm). Laminar lesions were made by either injecting small amounts of ibotenic acid into deep cortical layers with a 5 ~1 Hamilton syringe (0.05 ~1 injections of 10 rg ibotenic acid dissolved in 1 pl of physiological saline) or by making very large injections in one hemisphere (3 injections of 0.3 ~1 each) and analyzing receptor binding in the contralateral hemisphere. In the latter condition, limited release ofthe neurotoxin from the heavily injected hemisphere resulted in destruction of neurons in the superficial layers ofcontralateral cortex. As each ofthese injection procedurescould not be rigorously controlled, numerous cases were prepared for an experiment (i.e., 6-10) and screened histologically before receptor site analysis was undertaken. Following a 2 week postoperative survival period, animals were sacrificed with CO, and intracardially perfused with 50-100 ml cool (15°C) Krebs-Henseleit buffer. The brains were removed and frozen to -70°C in hexane. Cryostat microtome sections were cut at a 16 Frn thickness and mounted on subbed slides. A total of 4600 slides with 2 or 3 sections per slide were prepared and analyzed for these studies.
Unlabeled PZ was kindly provided by Boehringer Ingelheim, Ltd., while tritiated ligands, including PrBCM (specific activity, 43 Ci/mM), PZ (specific activity, 84 Ci/mM), OX0 (specific activity, 84.9 Ci/mM), and QNB (specific activity, 41.8 Ci/mM), were obtained from New England Nuclear. The in vitro protocol for the assay of PrBCM binding was similar to that employed by Rotter et al. (1979) . The assay for PZ binding was modified from Yamamura et al. (1983) and Wamsley et al. (1984) and included a preincubation in Krebs-Henseleit (30 min, room temperature), a 70 min incubation in PZ (15 nM, 24"C), 2 washes in Krebs-Henseleit (2 min each, 5"C), and rapid air drying. For the OX0 and QNB assays, there was a 25 min preincubation in 20 mM HEPESTris buffer including 10 mM Mg +2 at pH 7.5 and 23°C. Sections were incubated at the same temperature in either 10 or 0.1 nM OX0 for 30 min or in 1 nM QNB for 120 min. Throughout this study the abbreviation OX0 refers to the 10 nM concentration unless otherwise noted. Binding was terminated with two 2 min washes in cold (3°C) buffer followed by one 2 min wash in cold water and rapid air drying. Nonspecific binding was evaluated for all ligands by parallel incubation of a series of sections in radioactive ligand in the presence of 10m6 M atropine.
Two different autoradiographic techniques were used. For PrBCM the sections were dipped into Kodak NTB-2 emulsion, exposed for 3 weeks, develoned in Kodak D-19 (6°C) and fixed with Kodak Ranid Fix without hardener. For the PZ, 6x0: and QNB assays sections were apposed to coverslips coated with dried emulsion according to the technique of Young and Kuhar (1979) , exposed and developed as already noted for PrBCM. All sections were counterstained with thionin, but, since the PrBCM protocol includes a light prefixation step, morphological preservation and cytoarchitecture in this series was superior to that of the other series A computerized image-analysis system was used to count grain densities and determine specific binding. Readings per 2500 pm2 of a cortical layer were taken for total and atropine-blocked binding, visually corrected for miscounts due to overlapping grains and then subtracted to determine specific binding. Specific binding in 8 sublaminae in normal, unoperated cortices contralateral to ablated hemispheres and cortices from ablated hemispheres were determined in 2 or 3 sections per brain and means *SE calculated. Although binding in unoperated hemispheres of ATN ablated cases was similar to that of normal cases, ibotenic acid often spread to contralateral cortex, and so these cases were compared to unoperated controls processed exactly the same way.
Differences between means were evaluated with t tests (p 5 0.05).
Two issues are particularly important for interpretation of experimental localization findings. First, do lesions produce reductions in receptor density or affinity? A number of studies report that ablation and ligation techniques do not significantly alter muscarinic receptor affinity, but rather reduce receptor density (Briggs et al., 198 1; Kamiya et al., 1981; Zarbin et al., 1982; Andree et al., 1983; Mash et al., 1985) . Neither is affinity affected bv dissociation nrocedures (James and Klein. 1982) . In the present study,ablation-induced reductions in ligand bind: ing to muscarinic receptors are consistent with a loss of receptors on axons or dendrites. Second, does transneuronal degeneration account for alterations subsequent to deafferentation lesions (Hattori and Fibiger, 1982) ? As noted previously (Vogt, 1984) , 2 peaks in PrBCM binding in cingulate cortex were reduced by 40-50% following ATN or undercut lesions, and they remained after ibotenic acid lesions. We have explored ibotenic acid-ablated cortex electron microscopically and found that, although neurons are virtually nonexistent, axon terminals did remain (unpublished observations). This confirms the observation of Schwartz et al. (1979) that afferent axons remain intact in neurotoxin preparations. Thus, it is unlikely that reductions in receptor binding following ATN lesions are the result of transneuronal degeneration.
Results
Ligand specificity for the M2 receptor subtype Normal laminar binding profiles. PZ binding was essentially homogeneous, although binding was lowest in layer Ia and highest in layers Ic and II-III. Figure 1 presents the laminar binding profiles for PZ: PrBCM, QNB, and 0X0. The specific binding by layer is expressed as a percentage of all specific binding for all layers because absolute numbers derived from different experiments and using different autoradiographic techniques are not comparable.
Ligands that bound to both M, and M, receptor subtypes such as PrBCM and OX0 showed a marked heterogeneity in their laminar binding profiles, while the heterogeneity in QNB binding was not as pronounced. These heterogeneities were the reverse of PZ binding in that they tended to be highest in layers Ia and IV, where PZ binding was low.
Index of heterogeneity. Since the laminar distribution of PZ binding was essentially homogeneous and that of compounds which bound to both muscarinic receptors was heterogeneous, the greatest deviations from homogeneity reflected most efficient M, binding, i.e., least concomitant M, binding. A heterogeneity index was calculated by first determining the relative binding of each ligand by layer. Next, deviations from PZ binding were calculated for each ligand and the absolute values summed to determine the magnitude of variation as shown in Table l (A). These summed values were the index of heterogeneity.
though the total number of grains in one experiment was almost 2.5 times greater than in the other. Theoretically, variations in binding from 12.5% in each layer (i.e., 100%/8 layers = 12.5%) could have been used as a measure of absolute homogeneity instead of PZ binding. However, by using specific PZ binding, tissue artifacts such as differential laminar quenching of the tritium signal were standardized. In addition, there was no a priori reason to believe that M, receptor binding was absolutely homogeneous. Since the validity of the index was particularly dependent on A number of interesting points can be made from Table l(A). the relative distribution of PZ binding, and index of heterogeFirst, 10 nM OX0 had a lower index of heterogeneity than did neity was calculated for PZ itself from an entirely different exPrBCM. Second, a low concentration of OX0 (0.1 nM) had a periment. The index of 3.8 demonstrated that there was virtually higher index than did the 10 nM concentration. Third, blocking no difference in the laminar distribution of PZ binding, even the M, component of classical antagonist binding with 5 x 1O-8 0 Percentage distribution of specific PZ binding is presented for each layer in normal cortex. All other laminar distributions were calculated by subtracting these PZ percentages from the laminar pattern determined for each ligand. Where PZ is used as an unlabeled blocker, its concentration is lo-' M with PrBCM and 5 x 1Om8 M with OX0 and QNB. The absolute value of these percentage variations from the PZ distribution were summed to determine the index of heterogeneity. Each group represents a mean for 4-7 animals processed at the same time.
h Mean values of specific binding were calculated for 4-7 animals in normal and ATN-ablated hemispheres. Percentage changes in binding were determined for layers I-IV and summed. M unlabeled PZ produced higher indices than did high or low concentrations of OX0 alone. Fourth, the highest indices were those in which 5 x 1O-8 M unlabeled PZ was used to block either OX0 or PrBCM binding. Finally, although QNB had a low index, its index was improved proportionately more with PZ than were those for other ligands.
Muscarinic receptor subtype on axons of thalamic neurons Anterior thalamic ablations. The ATN project mainly to layer Ia of area 29~; there is less termination in layers Ib and IV and least in layers Ic-III. No termination occurs in layers V or VI (Vogt et al., 1981) . Lesions of the ATN failed to produce any significant alterations in PZ binding. The same lesions, however, consistently reduced PrBCM binding in layer Ia, while layer IV reductions were not always significant among the different experiments. Blocking the M, component of PrBCM binding by coincubation in various concentrations of unlabeled PZ uncovered the greatest ablation effects in layer Ia at 1O-8-1O-7 M PZ (Fig. 2 ). There were no changes in nonspecific binding following ATN lesions. In layer Ia of unoperated hemispheres, for example, nonspecific binding was 14.2 ? 0.37 grains/2500 pm* and 13.7 ? 0.45 in layer Ia of operated hemispheres. Note that effective concentrations to block the M, component of QNB and N-methylscopolamine binding (Luthin and Wolfe, 1984; Palacios et al., 1986 ) and the high-affinity component of OX0 binding (Bevan, 1984) would be in the lo-*-lo-' M range of PZ. Additionally, IC,, values were shifted after ATN lesions in superficial but not athalamic deep layers. Thus, IC,, values in normal layers Ia, Ib, and Ic were 1.3 x 10-6, 7 x lo-', and 2.1 x lo-' M, respectively. After ATN lesions they were 3.9 x 1O-7 and 1.6 x lo-' M for layers Ia and Ib, respectively, with no shift in layer Ic and only a small shift in layer IV. As can be seen in Figure 2 , there were no lesion-induced alterations in layer V. It is interesting to note that, in addition to having a stable postlesion I&,, layer Ic had the greatest proportion of all PZ binding (Fig. 1) . Figure 3 compares PrBCM and OX0 binding with and without unlabeled PZ. Only one significant reduction after ATN ablations in PrBCM binding occurred in layer Ia without PZ, however, with PZ significant changes in PrBCM binding occurred in 4 layers. Although significant alterations in OX0 binding occurred in layers Ia and IV, there was also a significant reduction in layer Ib following the PZ block.
Ablations of the ATN never reduced 0X0, OXO/PZ, Pr-BCM, or PrBCM/PZ binding to homogeneity, i.e., peaks in specific binding in layers Ia and IV remained postoperatively. In contrast, QNB/PZ binding was reduced to homogeneity by ATN ablations. In area 29c of unablated hemispheres (n = 4), specific QNB/PZ binding was as follows: Ia, 18 1 + 10; Ib, 102 f 8; Ic, 118 + 5; II-III, 143 + 11; IV, 153 f 9; Va, 122 + 10; Vb, 120 f 13; and VI, 79 * 4. In the ATN-ablated hemispheres binding was as follows: Ia, 119 + 15; Ib, 93 & 8; Ic, 106 + 10; II-III, 123 * 14; IV, 126 + 12; Va, 121 f 11; Vb, 115 + 15; and VI, 83 + 13.
Total percentage changes following ATN lesions. Since the ATN terminate in superficial layers and this was where significant reductions in binding occurred following ATN lesions, changes in binding in layers I-IV following ATN ablations were summed for each ligand. This produced a measure of the efficiency by which a ligand recognized M, sites associated with ATN axons. The total percentage reductions in OXO/PZ binding in layers I-IV was 125.1, and this value was greater than that for all other ligands tested [Table l(B)]. The rank order was as follows: OXO/PZ > OX0 (0.1 nM) = PrBCM/PZ > QNB/ PZ > PrBCM > QNB > PZ.
Based on both the index of heterogeneity and total percentage reductions in binding following ATN ablations, OXO/PZ and PrBCM/PZ were the most efficient ligands for M, sites.
Localization of dendritic M, receptors
Full-depth neurotoxin lesions. Ibotenic acid lesions were made in which there was relatively complete destruction of the full depth of parts of area 29~. In 8 such cases, specific PZ binding throughout area 29c was uniformly reduced by an average of 69% (Fig. 4) . In the same cases there was an overall reduction in PrBCM binding of 56%.
Laminar neurotoxin lesions. Full-depth neurotoxin lesions remove all neuronal somata and their associated dendrites and axons. In a number of instances, however, injections were either small and restricted to 1 or 2 layers or large, with spread into the contralateral hemisphere and subsequent destruction mainly of layers II-IV. These lesions were particularly valuable because alterations in binding could be evaluated in terms of the apical dendritic trees of pyramidal neurons. A photograph of one such lesion and its associated PZ binding is shown in Figure 5 . The generally high level of glial cells throughout ablated cortex suggested that perikaryal and dendritic loss had occurred throughout layers I-IV, as well as degeneration of the efferent axons of layers II-IV pyramidal cells that exit from the cortex via layers manner. Specific PZ binding was reduced most dramatically in layers I-III, with the greatest loss (78%) occurring in layer Ia. A smaller, though still significant loss of 38% occurred in layer IV. The reduction in layer Va was not statistically significant, and there were no differences in layers Vb or VI. In 2 other cases a lesion was made in layers Vb and VI. In these cases PZ binding was reduced in all layers superficial to the lesion, including lo-20% in layer I. V and VI. Figure 6 shows the PZ binding for 3 laminar lesions (i.e., neurons in layers II-IV were primarily destroyed) and 3 normal, unablated cases processed at the same time and in the same A, .
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-NORMAL 160 260 360 SPECIFIC PZ BINDING (GRAINS/2500 pm2) Figure 5 . Neurotoxin ablation of the granular layers II-IV of area 29~. A, Normal cryomicrotome section of area 29~. B, Ibotenic acid ablation of area 29~. Cortical shrinkage and gliosis was associated with these lesions. Gliosis in superficial layers I-IV was due to dendritic and perikaryal degeneration and that in deeper layers was associated with degeneration of efferent axons. C, PZ binding in the same case as in B. There was a clear reduction of binding in superficial layers, but it was normal in deep layers. This is one of 3 cases presented in Figure 6 . of QNB/PZ was reduced to homogeneity following ATN ablations (see above). Peak layer Ia binding was usually reduced by 40-50% for the former ligands. Although incomplete ATN lesions could account for some variation, complete undercut lesions also failed to abolish the layer Ia peak in PrBCM binding (Vogt, 1984) . In addition, ibotenic acid lesions always reduced peak binding of PrBCM and OXO/PZ in layers Ia and IV by about 50%. One explanation for persistent heterogeneity in binding following these lesions is that M, sites in layers Ia and IV are on both axons and dendrites. Full-depth ibotenic acid ablations reduced PrBCM binding in layers Ia and IV by 51 and 49%, respectively (Fig. 7) . The remaining peaks reflected binding to intact ATN axons because, following combined cortical and ATN ablations, PrBCM binding was reduced to homogeneity with losses of 91 and 82% in layers Ia and IV, respectively. In 3 cases assayed with 0X0/ PZ, cortical ibotenic acid injections reduced layer Ia binding by 75% and, when combined with ATN lesions, it was reduced to background levels.
Discussion
Three issues have been raised in the present study: (1) Structural indices were developed to rank order ligand potency for cortical M, receptors; (2) the muscarinic receptor subtype associated with thalamic axons was assessed, and (3) localization of M, and M, receptors to the dendrites of cortical neurons was accomplished with laminar and combined cortical and thalamic lesion techniques.
Ligand selection for M2 sites Pirenzepine is frequently used to identify M, muscarinic receptors in the CNS (Hammer et al., 1980; Watson et al., 1983; Luthin and Wolfe, 1984; Wamsley et al., 1984; Meyer and Otero, 1985; Spencer et al., 1986) . In the present study, summed deviations from the homogeneous laminar pattern of PZ binding were used as one means of identifying ligands that bound most efficiently to M, sites. A second structural criterion for an M,-selective ligand was the sum of all percentage changes in binding in layers I-IV following ATN lesions. Pharmacological studies usually determine the order of potency for a series of ligands with a measure of affinity. Drawbacks to this approach are the large amount of tissue required for each determination and the limited topographic and cell process resolution. The structural criteria developed here require the use of a range of most likely effective protocols followed by sublaminar assessment of normal and postablation binding to determine the potency order for a group of ligands. Although this approach is costly and timeconsuming, it provides an independent measure of pharmacological specificity that can be directly linked to structural entities. The 2 structural indices of M, binding indicated that, of the ligands tested, OXO/PZ and PrBCM/PZ were preferable for characterizing the distribution of M, sites.
QNB was not as effective at labeling heterogeneously positioned M, sites as were other multiple site ligands, and this difference may serve as a basis for further subtyping M, sites. Thus, the layer Ia peak for QNB was not nearly as pronounced as that for PrBCM or OX0 and a larger proportion of QNB binding was to M, sites, since PZ produced the greatest overall improvement in the QNB index of heterogeneity. Since ATN lesions reduced QNB/PZ binding to homogeneity, it is proposed that QNB failed to recognize dendritic M, sites. The literature raises 2 issues that are relevant to these findings. First, agonist and antagonist competition studies of QNB binding, as well as multiple site binding in the presence of Mgf2, suggest that QNB differentiates between receptors (Ehlert et al., 1981; Burgisser et al., 1982; Lee and El-Fakahany, 1985) , as may be the case in the present study. Second, it appears that the distributions of QNB and PZ binding parallel each other in cortical areas that do not receive ATN afferents (Watson et al., 1985) . These investigators suggested that QNB and PZ labeling may be postsynaptic.
In conclusion, it has been proposed that M, sites are heterogeneous based on studies of heart muscle and cerebral cortex (Giachetti and Mittman, 1985; Giraldo et al., 1987) . If it is true that M, sites are located on dendrites as well as axons in the cerebral cortex, it is possible that their binding properties can be differentiated pharmacologically.
Localization of axonal M2 sites
Biochemical studies support the notion that muscarinic receptors are on axon terminals and that many are of the M, subtype (Ganguly and Das, 1979; Nordstrom and Bartfai, 1980; Fisher et al., 198 1; Zarbin et al., 1982; Raiteri et al., 1984; Mash et al., 1985) . The following observations suggest that thalamic afferents to cortex have primarily M, receptors. First, layer Ia normally has peak PrBCM/PZ and OXO/PZ binding but lowest PZ binding, suggesting that the M, component of PrBCM and OX0 binding accounts for many of the layer Ia sites, a layer that receives most ATN input (Vogt et al., 198 1) . Second, ATN ablation greatly reduces PrBCM/PZ and OXO/PZ binding in layers Ia, Ib, and IV but has no effect on PZ binding in any layers. This laminar pattern in altered binding also closely approximates the structural distribution of ATN cortical afferents. Third, competition studies indicate that layers which do not receive thalamic input like layer V are dominated by highaffinity binding, while layer Ia, which receives most ofthis input, has a larger component of low-affinity sites. Layer V IC,, values are similar to those reported for cortical homogenates (Hammer et al., 1980; Watson et al., 1983; Luthin and Wolfe, 1984) . Fourth, ATN lesions uncover high-affinity PZ sites and shift IC,, values to lower concentrations. M, receptors on ATN axons are probably muscarinic heteroreceptors because ATN input is noncholinergic, i.e., does not have choline acetyltransferase activity (Kimura et al., 1981; Armstrong et al., 1983) . It is unclear as to how these receptors modulate transmitter release from axon terminals of ATN neurons. ACh has been shown to inhibit release of noncholinergic excitatory transmitters in the hippocampus (Hounsgaard, 1978; Valentino and Dingledine, 198 1; Rovira et al., 1983) . Since ATN afferents to cingulate cortex are probably excitatory (Finch et al., 1984) ACh might inhibit the activity of ATN terminals in cingulate cortex. However, since muscarinic heteroreceptors on dopaminergic terminals in the striatum enhance dopamine release, it is also possible, though less likely, that ACh enhances transmitter release from ATN terminals.
Localization of dendritic M, and M2 sites
Although an autoradiographic study of PZ and QNB binding to sections of neocortex indicated that the laminar distribution of each was essentially homogeneous in neocortex and did not differ in retrosplenial cortex (Wamsley et al., 1984) , earlier and more recent autoradiographic studies have suggested that there is a differential distribution of high-and low-affinity sites in neocortex (Wamsley et al., 1980; Spencer et al., 1986) . The present study of cingulate cortex shows that the relative distribution of cortical PZ sites is almost a reverse image of PrBCM/ PZ and OXO/PZ binding and provides direct experimental evidence for localization of these sites to pyramidal cell apical dendrites. The conclusion that cortical neurons have M, receptors is supported by 3 observations. First, in the present study there was an almost 70% loss of specific PZ binding following neurotoxin lesions. Second, ACh-evoked, slow depolarization in pyramidal neurons is PZ sensitive Prince, 1985, 1986) . Third, high-resolution autoradiographic localization of PZ-sensitive sites to dendrites and somata has been made with dissociated cortical neurons (Vogt et al., 1987) .
Alterations in the laminar profile of PrBCM binding in area 29c following a number of different surgical procedures serves as the basis for localizing M, and M, receptors to the apical dendrites of pyramidal neurons. Thus, the 2 peaks in PrBCM/ PZ and OXO/PZ binding in laminae Ia and IV remain after ATN lesions, PrBCM peak binding persists after undercut lesions (Vogt, 1984) , and cortical ibotenic acid lesions reduce, but do not abolish, peaks in PrBCM and OXO/PZ binding, although binding in all layers is reduced by all lesions except the undercut procedure. A combination of cortical and thalamic lesions abolishes the 2 peaks, indicating that both cortical neurons and afferents contribute to the M, component of classical antagonist binding. With which cortical cells is the layer Ia peak associated? Only small and fusiform pyramids in layers II-IV have apical tufts which arborize preferentially in layer Ia (Vogt and Peters, 198 1; Vogt, 1985) . This contrasts with the even distribution throughout layer I of multipolar, bipolar, and extraverted pyramidal cell dendrites and apical tufts of layers V and VI pyramidal neurons. Removal of the dendrites of neurons in layers II-IV or V and VI with discrete neurotoxin lesions produced a lO-80% reduction in PZ binding in layers I-IV. A nonaxonal location for M, sites was also suggested by Prince (1985, 1986) , who observed ACh-evoked, non-PZ-sensitive, rapid depolarizations in nonpyramidal neurons. The observations of the present study cannot discount, however, the presence of presynaptic M, receptors on the ascending axons of intrinsic cells nor the possibility that there is an overlap of ligand binding to a population of low-affinity M, sites in layers Ia and IV. In conclusion, since removal of cells in layers II-VI by ibotenic acid lesions reduces peak binding of PrBCM in layer Ia, it is suggested that the apical tufts of both small-fusiform and large pyramids have muscarinic receptors and that those of small-fusiform pyramids contribute to the laminar heterogeneity in PrBCM and OX0 binding.
In conclusion, intrinsic and deafferentation ablation procedures can be used with a high degree of resolution to localize varieties of muscarinic receptor subtypes in the cerebral cortex. The differential localization of muscarinic receptors in cingulate cortex described here provides a model assay system for evaluating receptor and structural specificity of muscarinic binding as new ligands become available. It is also reasonable to expect that the structurally based indices of ligand potency will be extended for use in studying structure-receptor relationships in other neurotransmitter systems.
